Results 121 to 130 of about 30,945 (225)

Inflammatory and Immunological Basis of Periodontal Diseases

open access: yesJournal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima   +3 more
wiley   +1 more source

Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Companion canines need advances in therapeutic options for solid tumour malignancies. Natural killer (NK) cell infusions offer a promising treatment modality in canines with solid tumours. Autologous natural killer products are limited by dysfunctional immunity and a manufacturing process that delays care whereas allogeneic NK cells offer the ...
Allison M. Weisnicht   +11 more
wiley   +1 more source

Cumulative Antigen Suppression Reduces Clonal Plasma Cell Evolution in Gaucher Disease

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2197-2213, September 2026.
ABSTRACT Chronic antigenic stimulation is implicated in the pathogenesis of monoclonal gammopathy and multiple myeloma, yet longitudinal human evidence linking sustained antigen exposure to modifiable clonal plasma cell evolution remains limited. Gaucher disease (GD), caused by biallelic GBA1 pathogenic variants, is characterized by accumulation of ...
Noor Ul Ain   +10 more
wiley   +1 more source

Nootkatone inhibits the progression of glioblastoma by activating the ATF4-CHOP-CHAC1 pathway

open access: yesMolecular Medicine
Glioblastoma multiforme (GBM) represents a primary brain tumor that is widely prevalent, and clinical drugs available for its treatment exhibit varying degrees of resistance. Nootkatone (NKT) is a functional sesquiterpene sourced from traditional Chinese
Qian Wang   +10 more
doaj   +1 more source

Immunomodulation of the Prostate Tumor Microenvironment Following Inorganic Arsenic Exposure

open access: yesJournal of Applied Toxicology, Volume 46, Issue 9, Page 3274-3287, September 2026.
ABSTRACT The tumor microenvironment (TME) influences prostate cancer (PCa) progression through stromal and immune interactions. Adipose‐derived mesenchymal stromal cells (ASCs) modulate immune tone, while inorganic arsenic (iAs), a widespread toxicant, is linked to immune suppression and carcinogenesis.
Joseph J. Shearer   +4 more
wiley   +1 more source

Recent Development in Solar‐to‐Hydrogen Conversion Systems

open access: yesWIREs Energy and Environment, Volume 15, Issue 3, September 2026.
This review compares three solar‐driven hydrogen production methods, photocatalysis (PC), photoelectrochemical cells (PEC), and photovoltaic–electrochemical (PV–EC) systems by examining their mechanisms, materials, stability, and efficiency. Nanocrystal‐based PC catalysts achieved the highest quantum efficiency (94%), while PV–EC and Si nanowire PEC ...
Rabia Zafar Ali   +3 more
wiley   +1 more source

Imidazole‐Extended Non‐Fullerene Acceptors With Tunable Crystallinity for Ultrasensitive, Ultrafast Near‐Infrared Organic Photodetectors

open access: yesAggregate, Volume 7, Issue 8, August 2026.
A two‐dimensional extended imidazole acceptor‐based organic photodetector delivers a lower dark current of 2.54 × 10−12 A/cm−2, peak detectivity of 1.08 × 1013 Jones, the widest linear dynamic range of 167.8 dB, and ultrafast response times of 307/319 ns. ABSTRACT Emerging optoelectronic tasks such as night‐vision imaging and wearable health monitoring
Chengwei Shan   +12 more
wiley   +1 more source

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy